Research programme: adoptive cell therapeutics - ImmaticsAlternative Names: IMA 101; IMA 102; IMA 201; IMA 202; IMA 203; IMA 300; IMA 301
Latest Information Update: 25 Aug 2016
At a glance
- Originator Immatics US
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Aug 2016 Immatics and the University of Texas M.D. Anderson Cancer Center plan a phase I/II trial in Solid tumours (Second-line therapy or greater) in USA (NCT02876510)
- 30 Sep 2015 Preclinical trials in Cancer in USA (unspecified route) before September 2015
- 26 Aug 2015 Immatics and The University of Texas MD Anderson cancer centre announced the launch of Immatics US to develop adoptive cell-based therapeutics for Cancer